Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT01458730
Previous Study | Return to List | Next Study

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01458730
Recruitment Status : Completed
First Posted : October 25, 2011
Last Update Posted : August 4, 2022
Nordic Cancer Union
Roche Pharma AG
Mundipharma Pte Ltd.
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.

Condition or disease Intervention/treatment Phase
Central Nervous System Lymphoma Drug: Immunochemotherapy Phase 2

Detailed Description:

The objective of the study is

  1. To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and intraspinal DepoCyte followed by temozolomide maintenance treatment in newly diagnosed primary central nervous system lymphoma
  2. To assess the long term outcome concerning neurotoxicity

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide.
Study Start Date : May 2007
Actual Primary Completion Date : October 2010
Actual Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Intervention Details:
  • Drug: Immunochemotherapy
    Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte

Primary Outcome Measures :
  1. Overall survival

Secondary Outcome Measures :
  1. response rate [ Time Frame: at completion of therapy ]
  2. neurotoxicity [ Time Frame: 1-10 years after completion of therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically verified primary central nervous system lymphoma No prior PCNSL treatment.
  • Patients treated with steroids alone are eligible
  • No signs of lymphoma outside the CNS
  • ECOG performance status 0-4
  • Age > 17 and < 76 years
  • Written informed consent from the patient or guardian

Exclusion Criteria:

  • Cardiac failure > 3
  • Pregnancy or lactation. Women of childbearing potential are requested to use an effective method of contraception to avoid pregnancy for a period from entry to the study and at least 3 months after the last study medication
  • Previous malignancy unless disease free for at least five years
  • Active infection.
  • Regarding tuberculosis, patients at risk should be tested for latent TB according local practice at each treating centre.
  • Positive HIV status
  • Organ transplantation
  • Serious psychiatric illness
  • Prior radiotherapy to the brain
  • Concomitant anti-inflammatory medication that cannot be discontinued
  • Creatinine clearance < 60 ml/minute calculated by Cockcroft and Gault formula
  • Peripheral blood count with granulocytes <1.5 x 109L or platelets < 100 x 109L
  • Serum bilirubin >1.5 times or ASAT and alkaline phosphatase >2 times upper limits of normal.
  • Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any component of Rituximab excludes patients from Rituximab treatment, but not from the remaining part of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01458730

Layout table for location information
Elisa Jacobsen Pulczynski
Aarhus, Denmark, DK-8000
Sponsors and Collaborators
University of Aarhus
Nordic Cancer Union
Roche Pharma AG
Mundipharma Pte Ltd.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Aarhus Identifier: NCT01458730    
Other Study ID Numbers: EudraCT No 2006-004772-12
First Posted: October 25, 2011    Key Record Dates
Last Update Posted: August 4, 2022
Last Verified: August 2022
Keywords provided by University of Aarhus:
Intraspinal Depocyt
Maintenance temozolomide
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases